So far, no specific targeted therapies have proven activity in uveal melanoma, but preclinical studies suggest potential benefit of inhibitors of c-mesenchymal to epithelial transition (c-Met), sarcoma (SRC), rat sarcoma (Ras), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) receptor tyrosine kinases, phosphatidylinositol-3-kinase-AKT pathways, and receptor tyrosine kinases and insulin-like growth factor type I receptor (IGF-1R) [4,5]. Here, AKT1 is linked to uveal melanoma.